EDIT - Earnings call transcript Q2 2020

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon and welcome to Editas Medicine Second Quarter 2020 Conference Call. All participants are now in a listen-only mode. There will be a question-and-answer session at the end of this call. Please be advised, that this call is being recorded at the company’s request. I would now like to turn the call over to Mark Mullikin, Vice President of Finance and Investor Relations at Editas Medicine.

Mark Mullikin

operator. you, Thank and call. everyone our quarter second Good welcome conference XXXX afternoon, to Earlier releases. two issued this we afternoon, press

The first medicines, press agreement of with release programs announces the for these development termination the of Editas ocular to returning control Allergan full Medicine. of our

release available press results financial prepared section approximately for our on second the our for of today’s two and A website its our of Investors remarks, XXXX. provides open replay updates completion. hours call the the second The Q&A. corporate quarter will will After after be we of call

make As expectations, those a which on results indicated may in those reminder, Act including these most during recent on forward-looking by the important various this as prospects the quarterly section and our forward-looking provisions the about discussed remarks various statements of a future Reform of is that materially Private report differ file company’s XX-Q, from with result Harbor XXXX. purposes SEC. Litigation of factors, we Safe of the the Factors Actual Risk constitute statements for call plans under Securities Form

even upon In our of representing specifically addition, statements views relied our as our if today, obligation to by any any disclaim any and Except be statements, not views views revise represent of as as date. forward-looking any should we subsequent only required forward-looking as law, or update change.

our Cindy Chief will Officer, to I call Executive over Now, turn the Collins.

Cindy Collins

joining for for second the you, XXXX. Mark. and call update Thank our quarter corporate everyone afternoon, you us Good thank of for

Robertson, Chief our our am Michelle to and Mark, I Scientific Albright, addition Charles In by; Chief Financial Officer. Officer; joined

the for building been of has XXXX editing pioneering organization strengthening sheet. CMC advancement of the and out and programs, balance our continuation the quarter an important gene second period of development The

cell us well to condition. and blindness, for treatments genetic leaves revolutionize cancer, All continue to the disease positioned sickle neurological this of

with business broader track the plan enabled like robust still recent scientific our I guidance Our a whose of on would has challenges pandemic. of I am we to the proud remain some and us review the of key given we facing implementation our community to continuity the accomplishments. momentum shared is continuing even are team last now quarter. considerable and more with COVID-XX dedication significant,

As mentioned, thrilled control patients. we of to be ocular vivo full medicine the are including our first Mark EDIT-XXX, regain to CRISPR to administered medicine, in

Our rights and with XXXX agreement has development agreement terminated Allergan returns AbbVie medicines into and with for have a commercialization we been that Editas. ocular entered to new

we as by will and previously Allergan, manufacturing to clinical out Editas. EDIT-XXX activities and regulatory Over activities the transition carried EDIT-XXX months, including activities, coming well as for

and and for manufacturing will we EDIT-XXX quality. clinical staff in EDIT-XXX purchase Additionally, development, and add inventory research, programs

our report on cell for I the We EDIT-XXX, differentiated this for filing cohort we of by hemoglobinopathies. am our trial the cleared least For costs. X/X on We the clinical low-dose adult been our lead dose at complete EDIT-XXX LCAXX, in one BRILLIANCE the dosing continuing by cell the progress to year adult that medicines we pleased our remain patients engineered have the remain medicine Phase track the patient and after of to sites are resume to program will for for dose year. for IND and cancer in mid-dose now sickle COVID-XX cell end related end that track disease. to

CRO well are sites. and have clinical to the investigator identify lead as We our beginning identified as

solid the treatment oncology We cell of medicine for continue to tumors. donor lead our an advance EDIT-XXX, IND-enabling for healthy allogeneic, studies NK candidate,

innovative with cell propel donor cell a both iPSC-derived generate tumors, to an for for Additionally, CasXXa and medicines we programs treatment NK advance Editas NK proprietary will medicine solid iPSC-derived transformative need continue believe for solution. our for solid tumors as area our our We well. healthy pressing engineering unmet to

for into years medicines. we space and lease provides all clinic, support and iNK our flexibility clinical a medicines with robust and pipeline recently two externally. our the including we Editas’ in both of these our EDIT-XXX manufacturing cleanroom engineered To and and development support advance the capabilities, as our EDIT-XXX agreement phase this we for preclinical to the internally program space pipeline activities Azzur signed perform and agreements. dedicated Securing perform control needed with cell us early the GMP continue co-work. As multiyear clinic. employees We build to cell advance analytical programs manufacturing ahead, our manufacturing to our we manufacturing towards announced important

entered who trials. their from supplying also Houston critical manufacturing include integrated distribution for and will raw support cell material, strategic Catalent, infrastructure finished into and product partnership vectors as with as Catalent’s facilities in Baltimore, support provide engineered clinical viral production, will well medicine and of storage We a and Philadelphia.

to build continue guide out our Boulder we Lastly, in to RNA. manufacturing facility manufacture

more the to the and quarter, continue in we past to On search Medical level, development Chief our a years At onboarded executive Officer, could We not the Officer. over employees Business programs experience advance we a we in accomplish any primarily CMC for our the front, hired investors. organizational has of toward clinic. XX the and Berdugo, of this Chief Gad than who support of biotech, XX continue without our

Scientific to execution. investment Albright among overview, strategic our turn pipeline and community would to the pipeline, additional in Officer, in significantly gross to sheet, medicine our offering $XXX thank I you. These million. our the confidence proceeds cell Charlie call of strengthen and updates. now development like of while vivo funds that of demonstrating the common resulted approach recent With engineered discuss continued our Chief in Our continued We enabling the balance stock approximately over best-in-class

Charles Albright

call data thanks, report with patient first today. dose I’ll our On we shared the medicines first were call, Earlier joining proud from BRILLIANCE editing the vivo strategy. start this trial. an Thanks, the constitute Cindy of with of EDIT-XXX the therapeutic to we everyone safety our vivo in first CRISPR dosing last clinical that or with dosing the of supported second weeks patient. and pillar medicine, the with in in first six for dosing the which year, patient

report today that We’re to clinical remains additional We presenting patient look three-month their stable following data patients the follow-up evaluation. EDIT-XXX of dosing near pleased first future. more forward to in the

EDIT-XXX ocular our for Syndrome XA. type next EDIT-XXX, program Following is Usher

With the from termination of program our agreement and to advance to materials we Allergan this studies. with Allergan, transition processes manufacturing Editas into IND-enabling will

to ocular beyond are in our using expanding our from our knowledge pipeline We indications programs. vivo ocular

disclosed, program. we’re to previously a strategy. in collaborating the of therapeutic cell our medicines, AskBio Switching As pillar engineered other strategic with neurology

EDIT-XXX for sickle cell without best-in-class an this for filing remains encouraged with are potentially year. EDIT-XXX IND track our We progress on disease for medicine hemoglobinopathies.

As mutations, decreases risks. to a beta-globin suppressed or leveraging locus fetal edit increases potential of our disease occurring human fetal reminder, cell by sickle EDIT-XXX symptoms. site our and human hemoglobin safety naturally increased hemoglobin The approach genetic proprietary for the CasXXa support the

from cells we pan-cellular package exist EDIT-XXX. efficiently In region. improved Importantly, site. these maintained the at edit cells add hemoglobin improved patients the does this and and increased not for BCXXA proof-of-concept this preclinical believe healthy We propensity. treatment. preclinical could showed derived indicative in fetal hematopoietic potential elevated EDIT-XXX the edited our vivo fetal support of cell oral that were following and properties stem stem and to the cells donor had more sickle disease an showed in These editing presented Further, sickling hemoglobin Further, BCXXA genetic presentation, approach at reduced induces we presentation clinic. in EHA. efficacy our an hematopoietic from human data will best-in-class in fetal into the this cells We we enhancer enhancer studies hemoglobin supporting expression, translate of

recent the eager with For the to year. sickle begun planning site material. and Phase preparation these an lead fourth Further, identified cell to manufacture disease Principal infrastructure clinical this investigator remain necessary a test In in Azzur for reasons, track this Investigator an to engaged IND quarter. file clinic our we trial, to selection are at the XXX the are X/X trial in and we’ve for provides CRO the on agreement meeting

transformational we off-the-shelf Cell-based shared, tumors. and need exists to medicines As have tumors differentiated Editas shown aim unmet we investment its medicines. major in though is solid in liquid growing where oncology. develop activity have The

capabilities We’ve tumors. lead candidate made cell a deliver derived our progress healthy allogeneic editing of donor to us proprietary with uniquely EDIT-XXX, NK for solid substantial Our treatment oncology. vision on our medicine the positioned for

studies. IND-enabling our continue We

congress of cells. our As and acquisition collaboration has these part intend We year. preclinical scientific this Sandhill data the NK updated later accelerated with program donor a efforts, of in present healthy from this to expansion

platform of support continue potential to vitro data at advance program, CRISPR/CasXXa cell NK believe These side We transformative option our that these We explores cell our tumor new medicine. Graft iPSC-derived avoiding cells, NK enhanced also that cells an the cytokine while show as therapies killing intrinsic such cell as the recently of these and iPSC-derived NK can an the shelf medicine and ASGCT. T of important in office release data presenting Host editing syndrome. properties properties engineered versus treatments treatment be effects

contain will program in we’ll multiple updates and changes, the genetic medicine later experimental further lead this Our provide year. on

over Robertson. the Michelle turn to I’ll Now our call Officer, Chief Financial

Michelle Robertson

advanced in Thank position good as everyone. forward. strong Editas you, financial our remains afternoon, we Charlie and programs

to from of March raised proceeds sheet compared cash, million, Our the recent The net from increase plan balance equity XXXX offering XXst, fund recent $XXX balance our operating marketable our our we have of cash in June million and The XXXX. XXXX. million we will as XXth, due equity as our proceeds and raised largely company’s expect securities equivalents $XXX.X strengthened to were current cash $XXX.X the offering. was into

execution clinic. analytical candidate funding development ex to includes all build of also We use of enabling advancement and further ongoing of of our BRILLIANCE enhancement programs. into advancement continue trial vivo both and our in preclinical of and and positioned out the vivo additional proceeds are our across and organization, CMC capabilities well clinical the the The of the our pipeline,

Research expense compared the revenues in $XX of in $XX.X in like non-cash income expansion last Total million compared to statement $X.X with for development quarter of to that period decrease primarily and stock attributed compensation were were quarter our out-license IND was $XX.X million reiterate last million, back professional provide million year. million, and our expenses in discipline expenses last Revenue fees organization. expenses was I’ll related same to administrative million support year. same increase same to enabling year. into with $XX.X for in now pipeline balance cash $XX.X $X.X compared The was million period strong expenses period of connection licensing. XXXX, The program I million, primarily General last fees. the development turn the that, EDIT-XXX fiscal operating the progress non-recurring the were current expenses I’d related attributable review to call lower compared our the net our to and our With our of over $XX studies capital. services sheet well for agreement. for second related for million R&D $X.X to million our for XXXX. to for our External and Now, allocations our includes expenses patent year. period Revenue Cindy. an to as of the the G&A to same to and as flexibility will commitment received $XX.X

Cindy Collins

trusted incredibly enabled proud that despite I’m COVID-XX. progress, clinical, remain partners tremendous from from dedication and corporate the employees challenges Michelle. you, have and at who of Editas, scientific the leadership, Thank the

that Editas the to medicines are genetic neurological to We excited of disease blindness, differentiated provide advance sickle and incredibly cell pillars of the cancer, revolutionize CRISPR to diseases. two treatment have the potential

As leader our medicine, gene to our strengthening editing to look position vivo broader with company additional in forward the we further and the only clinic programs in expansion to beyond an ocular. patient a and the the with space first CRISPR indications as treat to advancing

where in medicines, oncology hemoglobinopathies progress preclinical We generated editing has and differentiated CasXXa data our also vivo our with in our programs. in are excited proof-of-concept engineered cell

manufacturing recent agreements rapid progress across programs. these continuation enable Our the of our

employees, our and, across you the call and Q&A. our to editing up With your thank velocity of look shareholders, partnership of continued forward that, organizational efforts expand the platform to our continue of support. all reach Operator? gene for partners, will in We significant course, interest we will patients. and for physicians, with We open

Operator

first Thank Gena Instructions] you. from [Operator Our comes Barclays. with Wang question

now is line Your open.

Peter Kim

a beyond is two Gena. you do have My taking I best-in-class what maybe or question our I questions. additional I called more potentially you so And question I know Peter extent those translate you preclinical about a versus Hello. my that. This by to maybe clinical after CRISPR, example, had one to first guess about levels for is, XX% having Thanks. I to had in a on studies, benefit? for one additional think EDIT-XXX. and Thanks question XX% levels HbF that HbF XX% showed for XX% is, guess, threshold

Charles Albright

is this Charlie. Thanks, Sure.

So across cell see some the is normalized unlikely of you’ll increased more clinical an not, retrospectively that that disease in be and instance, or disease. while red or all effect sickle as symptoms, data progression are and see with although better. fetal that And have hemoglobin of to hemoglobin fetal of I that will elevation others the the close we progress hemoglobin for you’ll the the hemolysis, cell data, on markers normalization of and markers normal are from so the normalized those haven’t markers inductions, shows the to their think seen are induction XX% trials

Peter Kim

more at cleavage I HBGX]. Is Is in – of also Given one think any – that – [sic risk Got HGBX want being HGBX cutting would - an identical [sic the it, site X And there HGB HBGX HBG] and I is that’s all? [sic I of cleavage question out EDIT-XXX. thank an front be HBGX]? HGB between you. the issue and that, guess, site

Charles Albright

deletion talking of duplication about making because the and – HBGX the of the You’re X

Peter Kim

– yeah Yeah, yeah,

Charles Albright

think – I that’s event right rare we question. that’s know really a Yeah, now. that’s a

not – and in concerned one, we’re we’re rare a So event. secondly, number it’s not very general

Peter Kim

issue. event no Okay. is And that rare safety

Charles Albright

No, one [indiscernible]. issue. just it It’ll – won’t missing the will two be HBG be of an

Peter Kim

much. Okay, great. Thank very you

Operator

you. Thank

Morgan next from Stanley. Matthew Our Harrison with question comes

Your now open. line is

Max Skor

about Matthew or Skor for much. initial provide Could program? the Max regarding royalty Thank additional you range taking on very with deal? you we associated And how clinical and for Harrison. think color is for milestones timelines gating questions. Thank AbbVie you this our Hi, new any factors the the should USHXA

Michelle Robertson

I’ll of take So yeah, question. first part that first – I’ll take the the

QX terms we to not the the that. XXXX. into part material one pay that way we obligated cash our will disclose AbbVie So jointly let is quarter. I’ll we’re agreed still to would us second take however, in And payment with And financial this Charlie the which of in not take

Cindy Collins

timeline I’ll answer the question.

Editas. to have we timeline some we prepared to with impacted at to the to manufacturing assets activities be few transfer all. of back a transition And associated of control we indicated be thrilled these are able LCAXX is the So, regain And transferring will will be we remarks, going as of well. the services the that really not as in

occur we’re all clinical going because So to today’s speak on activities not to perspective. call, need and transition the timelines we a regulatory, need to assimilate manufacturing that from to

Max Skor

you. thank Great,

Operator

Thank you. Company. Cowen And Phil our with next question & comes Nadeau from

now Your is open. line

Phil Nadeau

thanks afternoon questions. Good for and taking my

they such in back to on the bit those priorities is little the weren’t rights about back AbbVie, question the any Allergan. change Editas particularly Can or gave after the of what Allergan get the that you program a to to with at First merger ending seeking follow-up talk and a longer? the decision deal where, the rise opportunistic was the rights interested

Cindy Collins

the that the speak that want know, of they, was, speculate AbbVie on this I portfolio, that best certainly these you were Editas. for certainly what assets were within or but originated we we given and thrilled rationale had behalf the don’t home has and technology identified So believed for to

Phil Nadeau

those think What of before Okay, completed fair on XXX. IND the question COVID? and enough. activities second then to And because risk I remains be is at

Charles Albright

the the the them now. IND of to the activities or which of were to activities All end all tail get at right typical

end And incredible we year. really team IND from we’re on file required that’s of remain this by – the year. the effort to the So the still track a

Phil Nadeau

questions. Great, taking thanks my for

Operator

Thank you.

Seedhouse next comes Steve with Our Raymond James. from question

open. now Your line is

Steve Seedhouse

Charlie LCAXX in the three-month to the for the safety mentioned the study health stable patient to you I follow-up. respect remained first is just want thanks and with you are referring context or a that question. vision clarify overall following in to Great, stable there?

Charles Albright

also is vision patient. stable The in that

dosing the from update the so eagerly that await patient. second And next the we in of

Steve Seedhouse

so increasing clear. decreasing be stabilized Okay, to not and nor

Charles Albright

right. Right,

Steve Seedhouse

that just Or on ophthalmology? Okay. beyond AbbVie. with the that new the clarify now contemplated Editas this you programs programs? is just include And previously other then – also Could to deal restricted does if

Cindy Collins

These part agreement. the programs of XXXX that were are the Allergan

LCAXX, identified. are, be program fourth USHXA to they So and RPX to and

Steve Seedhouse

Okay, as interest technology was question, just pursuing you And base editing comment base has that thanks. last I in already platform? on could editing hoping if supplement your editing any a gene to broad

Charles Albright

and interesting We CasX at understood editing I’ll feel lot talk as we it do and be See we technology. early comment it looked a about an still from to we the need on, with base can the And own it’s leave science platform. standpoint distinct of to a combination else. CasXXa. the do importantly, somebody is business there’s what base technology to editing

with We’re where happy we are.

Steve Seedhouse

Thanks right. All the for questions.

Operator

you. Thank

Securities. from Wells Fargo Our next question Yanan with Zhu comes

Your line open. is now

Yanan Zhu

questions. Hi, thanks for the taking

The the regarding of regaining first question the rights.

AbbVie the from Just generated wanted to has seen data confirm any first clinical patient?

Cindy Collins

the program at an co-commercialization Editas as the you as is to LCAXX Allergan co-development, the development table Yes, was and program, trial. and seed that at the both might active had clinical clinical it related the recall,

Yanan Zhu

a And it? the I of program. more near on the could Got EDIT-XXX little give think color the Charlie future you timing mentioned data? for

Thanks. on as difficult the when report it��s your very if to some on you or decision So a timing. such criteria number share patient of Could follow-up be time? to specific

Cindy Collins

So is year. this to The will I’ll start. we hope have that later data share

first patient. As you we’ve know, the treated

the move well patient. forward year. We patient in to, the dose trial of now. and this through and have we successfully screen X open to think seeing the are And know, X And second the patient next the clinical the as sides cohort you as first are patient AbbVie continuing we’ll process second and map for dosing in patients we cohort in clearance

like, take don’t know, to largely you have and of will color? dataset we it, decision, the you robustness from we’ll collectively depend other and it that patient-by-patient what looks add want the I to on see Charlie on a if So the know, what study, you know any

Charles Albright

absolutely that’s right. think I

eager an representation a investor's sense standpoint you We’re in talk to makes and being release timeframe we’ll the what’s that accurate know it both, about and of happening. from an, a a data in

Yanan Zhu

healthy such NK, share I a on color product is Could as CAR your NK some And mentioned antibody rather EDITs? anti-EGFR. such like iteration the with it program. previously of Got looks many therapeutics high-level And to you first you anti-HERX the it. as think it’s how EDIT-XXX what’s not donor works

know, So timing regard will the – of data? with also Thanks. that year, EDIT helpful. any, be characterization mates further later very preclinical little the you of that preclinical And you more this on specific would be in be data a to able to

Charles Albright

Sure, look preclinical we this to forward package later do EDIT-XXX full providing for a year.

And going to we that on hold because into we meeting. get that to so hope are – scientific off we’re a

the We’re meeting, accepted it submitted which get and tell abstracts whether about reluctant talk or to on all getting to we you posture, cetera. a depend – because and et

we it any want talk going or about things. one this to do it to robust really meeting. a So scientific we about of we’re to other want year talk wouldn’t bias to But the so way have those hopefully

Yanan Zhu

last Great. Then question.

of what’s from like you position, of that iPSC straight of your the thought method How is also the property iPSC in What could deriving it’s there? obviously, licensed from IP, iPSC platform? method differentiated speak overlap? Is Blue there others, platform program any And intellectual terms cells? – Thanks. therapeutics Regarding the Rock. to

Charles Albright

to what realize accessing so qualified with thing simple got to from iPSC that is Rock were we do the specific not the significantly. alliance to GMP important that a allowed that’s Blue Blue that program way it’s lines first accelerate And seed because lines. in GMP important Well qualified really Rock us Sure.

in medicines, world-class Right middle position us IP a good we’re both very in platform. CasXXa. of using So a is doing and a CasX editing platform as our puts a world-class merging enzyme what We’ve position. quite as and about property it’s bit talked it and a for CasXXa the we’re great IPSC creating our foundational intellectual in cell-based well now

that property that our developing avoid have We’re intellectual need to so own the others far. methods we

Yanan Zhu

Charlie. Thanks,

Rock Blue iPSC with I meant that Sorry any platform, that whether have platforms? the, how know, you IP iPSC the technology position for other whether the overlap

Charles Albright

I on probably right the wouldn’t the we’re to for want feel And that property position comment with Rock. to intellectual not in. Blue we I’ll say person comfortable just – I’m

Yanan Zhu

Thank you.

Cindy Collins

question Lee there from There other with Operator, Joon any Truist my are questions? is, Securities. apologies. A

line open. is now Your

Joon Lee

taking on for and Thanks progress. congrats guys. questions the Hi, my

is as improvement ocular Just o'clock know, visual following by But is on the mentioned recall a month, able stable. correctly. they safety is vision Charlie ProQR’s five the program, thing. up you to program, were three, It that program, stable see antisense the I good and you

You And to wait? know, how see I long think to would efficacy? a follow-up. you an you need have Do

Charles Albright

the thing about perception I Yeah, seeing we’ve number important it’s life small recognize and patient low-dose. is that before a I months. only, talked efficacy this a in to of mean, think

for see is in efficacy going to this most us the to So place be difficult study. this

So fulsome we’re a the out look datas there. eagerly awaiting at

Joon Lee

NK allo strategy, you regarding have cell and an program. and induced Okay an NK

the indication You are sort divvy cannibalistic? synergistic up more you how they look very? to they are Are they know, because of or or planning

Charles Albright

We’re so making to in differentiated don’t we each areas, we’re making two the other as expect other. products cannibalize medicine,

to they’re subsequent some healthy NK donor that expect or be for learn relevant program products, we donor to fact, test will whether or biological from the healthy hypotheses things EDIT-XXX iPSC-derived. In

Joon Lee

Okay.

for and will different diseases allo these diseases? So be same NK induced the or developing you cells

Charles Albright

haven’t the We due come a sensitivity course, perspective. have competitive again, from there's in indications disclosed that’ll we this yet, around

Joon Lee

just, whether labs so, get your benefit did those there know, still company? that the course, how that you do or of was And decided academic you it to Of from scientific then yeah. some you if other company? IP goes guys co-founders, or discoveries, And

Charles Albright

to entire the among with the can to. the we Yeah, our world are talked we’re we obviously folks founders extent in contact

the we’re lookout to leave platform. improve And that just I for would constantly so, that make technologies it that, our sense at on

Joon Lee

you. thank Great,

Operator

next our question Thank you. from And Jay Oppenheimer. comes Olson with

now line open. Your is

Jay Olson

question. the taking Hi, thanks for

regained portfolio. regards Just was Are with that there direction the now ocular or AbbVie would on change curious the decisions in to you would differently you that things strategic to any that the the you that now to you those make that XXX have decisions development rights moving independently? make to of freedom clinical either I follow-up or full deal. programs

Cindy Collins

I able you We direction to to because clinical decisions strategic the more any have and development the have or think joint would intention that, don’t be know, make say to programs the rapidly. I advance we quickly, be change to we’ll make decisions able strategy. more don’t

Jay Olson

great. Okay, share design to towards that. just on about age And in XXX for populations, terms genotypes? any Thank are regards you patient there segmentation you IND, of progress an as numbers trial then can or initial thoughts with and patient or you clinical

Charles Albright

Yeah, getting to and want really we and really patients but this the I think that don’t priority a Clearly, we comment point. to on want comment wouldn’t getting top IND is at for this details I that at – on the pass the I us, point.

Jay Olson

Thanks Okay, taking understood. for the questions.

Mark Mullikin

to Thank and call I’d time, like Collins At turn closing no queue. Cindy to I’m for questions further the showing back remarks. this the in you, any

Cindy Collins

Great.

all participating you thank call today’s patients. your be to work medicines and transformative we safe. that, with Take care as for in we support to So bring new and for

Mark Mullikin

you program and disconnect. and participation you does conference. conclude for Ladies on gentlemen, thank may now your your This today’s

Editas Medicine (EDIT) 6 Aug 202020 Q2 Earnings call transcript